Cue Biopharma (CUE) Stock Price
Cue Biopharma Price
Over the last 7 years Cue Biopharma grew revenue by 57.5% annually, reaching 27.47 M USD. For Cue Biopharma, the net margin of -96.9% is up versus -295.6% a few years ago. The consensus 12-month price target for Cue Biopharma is 8.16 USD, about 67.7% below where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
Cue Biopharma stock price
Cue Biopharma business model & stock analysis
Frequently asked questions about Cue Biopharma
Cue Biopharma Inc is a biotechnology company with a unique business model. It focuses on developing a novel class of biologics called immuno-modulatory proteins (CMPs) to treat a wide range of cancers and autoimmune diseases. By leveraging its Cue Biologics platform, the company aims to engineer CMPs that can selectively modulate immune responses, enhancing the body's ability to fight diseases effectively. Cue Biopharma Inc's business model revolves around creating innovative therapies that leverage the power of the immune system, offering a promising approach in the field of precision medicine.
Cue Biopharma Inc is primarily active in the biotechnology industry.
The main competitors of Cue Biopharma Inc in the market include leading biopharmaceutical companies such as Bristol-Myers Squibb, Eli Lilly and Company, and Merck & Co. These companies also operate in the field of immunotherapy and targeted biologics, which aligns with Cue Biopharma's focus on developing novel biologic therapies for various diseases. Through their extensive research and development efforts, these competitors strive to provide innovative treatments that can effectively address the unmet medical needs of patients.
Cue Biopharma Inc is a biopharmaceutical company founded in 2015. The company focuses on developing innovative immunotherapy drugs for the treatment of various cancers and autoimmune diseases. Cue Biopharma combines insights from immunology and protein engineering to create drugs that enhance the body's immune response against these diseases. With a strong emphasis on precision medicine, Cue Biopharma aims to address the limitations of current treatment options by developing therapies that target specific disease-causing molecules. Through its cutting-edge platform, the company is committed to advancing the field of immunotherapy and improving patient outcomes.
Cue Biopharma Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in October 2017, raising $66.5 million. Cue Biopharma Inc has advanced multiple programs and entered into several strategic partnerships. It has collaborated with Merck under a multi-year collaboration to develop a potential treatment for cancer. Furthermore, Cue Biopharma Inc has leveraged its proprietary platform technology, Immuno-STAT, to create a pipeline of potential immunotherapies targeting various diseases. The company has made remarkable progress in the field of biopharmaceuticals, positioning itself as a leader in the development of innovative immunotherapeutics.
Cue Biopharma Inc is primarily present in the United States.
Cue Biopharma Inc represents values of innovation, dedication, and collaboration in the biopharmaceutical industry. The company strives to develop novel and advanced immunotherapies to address critical unmet needs for patients. With a corporate philosophy centered around precision medicine and immuno-oncology, Cue Biopharma is committed to harnessing the power of the immune system to fight against cancer and other diseases. By leveraging its innovative Immuno-STAT™ platform, the company aims to create highly targeted therapies that can revolutionize the treatment landscape. Cue Biopharma's focus on cutting-edge science and strategic partnerships reflects its dedication to improving patient outcomes and advancing the field of immunotherapy.
Analysts currently set an average price target of 9.59 USD for the Cue Biopharma stock (median: 8.16 USD), implying -62.0 % versus the latest price. The consensus is based on 9 analyst ratings.
6 analysts currently rate the Cue Biopharma stock: 5 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Cue Biopharma to generate revenue of 15.62 M USD and earnings per share of -534.58 USD.
Converted at the current exchange rate, the Cue Biopharma share trades at 22.53 EUR (25.25 USD).
The Cue Biopharma share (CUE) is listed on 3 stock exchanges, including: NASDAQ (CUE), Frankfurt (1UC.F), München (1UC.MU).
Cue Biopharma Inc is a biopharmaceutical company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts. The business model of Cue Biopharma Inc is based on the use of immunotherapies targeting the body's immune system to fight cancer and autoimmune diseases. The company utilizes a unique platform called Immuno-STATs (Signal Transducer and Activator of Transcription Proteins) to create artificial proteins specifically targeting T cells in the immune system. These proteins can then be used to selectively activate the immune system and attack diseased cells in the body. Cue Biopharma Inc focuses on developing tailored immunotherapies customized to each patient's individual needs. The company is divided into several business areas, including research and development, clinical trials, and commercial production. Cue Biopharma Inc collaborates closely with leading researchers and scientists in the field of immunology to leverage the latest advancements and technologies. Cue Biopharma Inc currently offers several products, including CUE-101, CUE-102, and CUE-103. CUE-101 is an immunotherapeutic currently in phase 1 clinical trial for the treatment of HPV-associated cancer. CUE-102 and CUE-103 are still in preclinical development but have shown promising results in studies. CUE-103 is primarily intended for the treatment of autoimmune diseases such as type 1 diabetes and rheumatoid arthritis. The company is committed to continuously researching and developing better and more targeted immunotherapies to help millions of people worldwide. In summary, Cue Biopharma Inc is an innovative company specializing in the development of tailored immunotherapies for the treatment of cancer and autoimmune diseases. The company utilizes a unique technology to selectively activate the immune system and attack diseased cells in the body. Through close collaboration with leading researchers and scientists in the field of immunology, as well as ongoing research and development, the company aims to develop increasingly better and more effective therapies.
The expected revenue of Cue Biopharma is 15.62 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Cue Biopharma is -1.97 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Cue Biopharma is currently -0.05. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cue Biopharma stock.
The price-to-sales ratio (P/S) of Cue Biopharma is currently 5.95. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cue Biopharma stock.
The Eulerpool Quality Score for Cue Biopharma is 4/10.
The ISIN of Cue Biopharma is US22978P1066. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Cue Biopharma is A2JAT5. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Cue Biopharma is CUE. The ticker symbol is used to trade Cue Biopharma shares on the stock exchange.
Cue Biopharma stock
Cue Biopharma Peer Group
Cue Biopharma Ticker
Cue Biopharma FIGI
All fundamentals and in-depth analysis of Cue Biopharma
Our stock analysis for Cue Biopharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cue Biopharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.